Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis
المؤلفون المشاركون
Wang, Jia
Li, Ya
Wang, Chong
Zhang, Yayue
Gao, Chong
Lang, Haiyan
Chen, Xinyi
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-12-12
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Objective.
To conduct a meta-analysis, assessing the efficacy and safety of the combination treatment of dexamethasone and rituximab for adults with ITP (primary immune thrombocytopenia).
Methods.
Randomized controlled trials that compared rituximab and dexamethasone combination treatment to dexamethasone monotherapy in the treatment of adults with ITP were collected by searching Pubmed, Embase, Cochrane, China National Knowledge (CNKI), Wanfang database, and Sino Med.
We conducted pooled analyses on OR (overall response) rate, CR (complete response) rate, PR (partial response) rate, SR (sustained response) rate, R (relapse) rate, change in Treg cell count (mean [SD]), and AE (adverse event).
GRADE pro scale was used to assess the quality of the evidence.
Publication bias was assessed with Egger’s test method.
Results.
A total of 11 randomized controlled trials were eligible for inclusion.
The overall efficacy estimates favored combination arm in terms of OR rate at month 3, CR rate at week 4 and month 3, SR rate, and Treg cell count at week 2.
Subgroup analysis showed that females obtained a higher OR rate than males did at week 4.
No significant difference was found in pooled analysis of relapse rate between combination arm and monotherapy arm.
The comparison of serious AE and other AEs showed no significant difference either.
A total of 19 outcomes were assessed by GRADE pro software, of which 79% (15/19) was scaled as moderate-to-high level.
Publication bias existed in studies on OR at week 4 (P=0.025), CR at week 4 (P=0.017), infection (P=0.006), and rash (P=0.028) of the AEs.
Conclusion.
Dexamethasone combined with rituximab can provide a better long-term response in the treatment of adults with ITP and will not increase the risk of adverse effects.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wang, Jia& Li, Ya& Wang, Chong& Zhang, Yayue& Gao, Chong& Lang, Haiyan…[et al.]. 2018. Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis. BioMed Research International،Vol. 2018, no. 2018, pp.1-12.
https://search.emarefa.net/detail/BIM-1124239
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wang, Jia…[et al.]. Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis. BioMed Research International No. 2018 (2018), pp.1-12.
https://search.emarefa.net/detail/BIM-1124239
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wang, Jia& Li, Ya& Wang, Chong& Zhang, Yayue& Gao, Chong& Lang, Haiyan…[et al.]. Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-12.
https://search.emarefa.net/detail/BIM-1124239
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1124239
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر